Lingkai Pharmaceutical is a small molecule drug developer and a high-tech enterprise that provides professional CDMO services to global innovative drug companies and new energy companies in accordance with international standards. Recently, Huashen Technology announced that Huashen Xingrui, a wholly-owned subsidiary of the company, increased its capital in Shanghai Lingkai Pharmaceutical Technology Co., Ltd. with no more than 200 million yuan. After the capital increase, the company will hold 5.7143% shares of Lingkai Pharmaceutical through Huashen Xingrui.
This article is reproduced from: https://www.itjuzi.com/investevent/13584017
This site is for inclusion only, and the copyright belongs to the original author.